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that, individually, these genes are not essential for via-
bility. To investigate whether there is functional redun-
dancy, we have generated double knockout (DKO)
mice.Cdk22/2Cdk42/2DKOsdieduringembryogenesis
around E15 as a result of heart defects. We observed
a gradual decrease of Retinoblastoma protein (Rb)
phosphorylation and reduced expression of E2F-target
genes, like Cdc2 and cyclin A2, during embryogenesis
and in embryonic fibroblasts (MEFs). DKO MEFs are
characterized by a decreased proliferation rate, im-
paired S phase entry, and premature senescence.
HPV-E7-mediated inactivation of Rb restored normal
expression of E2F-inducible genes, senescence, and
proliferation in DKO MEFs. In contrast, loss of p27 did
not rescue Cdk22/2Cdk42/2 phenotypes. Our results
demonstrate that Cdk2 and Cdk4 cooperate to phos-
phorylate Rb in vivo and to couple the G1/S phase
transition to mitosis via E2F-dependent regulation of
gene expression.
Introduction
Cell proliferation is controlled by cyclin-dependent ki-
nases (Cdks) (for review, see Malumbres and Barbacid,
2005; Morgan, 1997). The sequential phosphorylation
of the retinoblastoma protein (Rb) plays a pivotal role in
the G1/S phase transition (Bartek et al., 1996; Mittnacht,
1998; Weinberg, 1995; Zarkowska et al., 1997). In its hy-
pophosphorylated state, Rb sequesters and represses
the E2F family of transcription factors (Weinberg,
1995). Mitogenic growth factors induce phosphorylation
of Rb by activation of cyclin D-Cdk4/6 and cyclin E/Cdk2
*Correspondence: kaldis@ncifcrf.govcomplexes. This results in release of E2F proteins from
Rb and promotes transcriptional activation of genes re-
quired for S phase and DNA replication (Ezhevsky
et al., 2001; Harbour and Dean, 2000; Harbour et al.,
1999; Lundberg and Weinberg, 1998). Conversely,
growth-inhibitory signals reduce cyclin levels or induce
Cdk inhibitors (CKIs), resulting in decreased cyclin/Cdk
activity, hypophosphorylation of Rb, and, subsequently,
in repression of E2F-target genes (for review, see Ruas
and Peters, 1998; Sherr, 2001; Sherr and Roberts, 1999).
Mouse models have been developed in order to better
understand the G1/S transition of the cell cycle and the
interplay of the cyclin/Cdk complexes. Inactivation of in-
dividual genes encoding members of these complexes
(cyclins D1, D2, D3, E1, and E2 and Cdk2, Cdk4, and
Cdk6) has revealed that none of these proteins consid-
ered to be important for the control of the G1/S transition
are essential for viability per se and that their loss causes
few cell cycle defects (Berthet et al., 2003; Fantl et al.,
1995; Geng et al., 2003; Malumbres et al., 2004; Ortega
et al., 2003; Parisi et al., 2003; Rane et al., 1999; Sicinski
et al., 1995, 1996; Tsutsui et al., 1999). For example, male
and female Cdk22/2mice are sterile but otherwise com-
parable to wild-type mice. Mouse embryonic fibroblasts
(MEFs) derived fromCdk22/2 embryos display a delayed
entry into S phase and are not efficiently immortalized
(Berthet et al., 2003; Ortega et al., 2003). Cdk42/2 mice
are substantially smaller compared to wild-type mice,
develop diabetes spontaneously, and are sterile (Rane
et al., 1999; Tsutsui et al., 1999). Cdk42/2 MEFs display
a delayed entry into S phase concomitant with low
Cdk2 activity due to increased p27 binding. This defect is
partially rescued by the loss of p27 (Tsutsui et al., 1999).
Further studies used double (DKO) or triple knockout
(TKO) mice to characterize in vivo functions of each sub-
family (D-type cyclins, E-type cyclins, Cdk4/Cdk6) and
potential compensatory mechanism. Indeed, ablation
of the three D-type cyclins leads to embryonic lethality
around E15.5, which is associated with a cardiac output
failure and severe anemia (Kozar et al., 2004). Similarly,
inactivation of Cdk4 and Cdk6, partners of D-type cy-
clins, results in a late embryonic lethality with severe ane-
mia (Malumbres et al., 2004). Both models indicate that
D-type cyclin/Cdk4 and cyclin/Cdk6 complexes are in-
volved in development of the hematopoietic lineage,
but that, overall, they have little effect on cell proliferation
and organogenesis. Analysis of MEFs confirmed that in-
activation of Cdk4 and Cdk6 or D-type cyclins delays S
phase entry (or reentry after serum starvation) but does
not prevent proliferation (Kozar et al., 2004; Malumbres
et al., 2004). In contrast, cyclin E12/2E22/2 DKO MEFs
proliferate, but they fail to exit quiescence owing to a de-
fect in loading of MCM proteins onto DNA prereplication
complexes (Geng et al., 2003). In vivo, DKOs of cyclins E1
and E2 result in embryonic lethality due to defective tro-
phoblast endoreplication (Geng et al., 2003; Parisi et al.,
2003). All of these findings suggest that D-type or E-type
cyclin complexes are not essential for proliferation
in vivo and in vitro (with the exception of exit from quies-
cence for E-type cyclins), and that these complexes
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cycle progression. As a first approach, Malumbres et al.
(2004) have generated Cdk22/2Cdk62/2mice, which are
viable and do not exhibit cell cycle defects. However, si-
lencing of Cdk2 in Cdk42/2Cdk62/2 MEFs significantly
affected the proliferation rate, indicating that at least
one of these Cdks is required for the G1/S transition.
Cdk2 andCdk4 are located on the same chromosome,
which renders the generation of DKOs difficult. We were
able to generate Cdk22/2Cdk42/2 mice, and, interest-
ingly, they exhibit embryonic lethality and cell cycle
defects, unlikeCdk22/2Cdk62/2mutants, which empha-
size overlapping functions shared by Cdk2 and Cdk4.
Results
Generation of Cdk2 and Cdk4 DKO Mice
Cdk2 and Cdk4 are located on chromosome 10D3 and
are only 1.6 Mb apart (Figure 1A). We crossed Cdk2+/2
with Cdk4+/2 mice (Berthet et al., 2003; Tsutsui et al.,
1999) to generate Cdk2+/2Cdk4+/2trans mice and back-
crossed those with C57BL/6 mice. Most of the resulting
pups were heterozygous for Cdk2 or Cdk4, except
when a meiotic crossover occurred between the two
gene loci. Meiotic crossovers occur at a frequency of
1% per 2 Mb distance in the mouse genome (Silver,
1995). In theory, 0.8% of animals generated from our
backcrosses should be either wild-type or ‘‘cis’’ double
heterozygous. We selected the latter animals, which car-
ried both recombined loci in ‘‘cis’’ on chromosome 10
(Figure 1B). Out of 245 pups, we detected 3 double het-
erozygous and 3 wild-type mice; thus, we believe that
a total of 2.4% recombination events occurred between
these loci (Figure 1A). The chromosomal region 10D3 is
close to the telomere, a region more susceptible to re-
combination, especially in males, which might explain
the increased levels of recombination (Silver, 1995). We
backcrossed Cdk2+/2Cdk4+/2cis mice to confirm that
both loci are linked and generated a colony for each
founder. We then intercrossed Cdk2+/2Cdk4+/2cis mice
to generate Cdk22/2Cdk42/2 DKOs. Western blots
from embryo extracts were performed and confirmed
the absence of Cdk2 and Cdk4 proteins (Figure 1C).
In our crosses, we occasionally observed single het-
erozygosity for one gene associated with wild-type, or
null locus for the other gene. These genotypes required
a meiotic recombination to revert the link between
Cdk2 and Cdk4 mutant loci. This reversion occurred at
a frequency of 7%, suggesting, again, that this chromo-
somal region is highly susceptible to recombination.
Among the offspring, we found some Cdk22/2Cdk4+/2
or Cdk2+/2Cdk42/2 mice, which were viable (data not
shown).
Cdk22/2Cdk42/2 DKO Mice Are Embryonic Lethal
From the Cdk2+/2Cdk4+/2cis intercrosses, no living
Cdk22/2Cdk42/2 pups have been found; however, em-
bryos lacking Cdk2 and Cdk4 were observed (Fig-
ure 1D). The embryonic lethality indicated that Cdk2
and Cdk4 have overlapping essential functions in vivo.
Normal Mendelian ratios persisted until E13.5, but, at
later stages, a significant percentage of Cdk22/2
Cdk42/2 (DKO) embryos were found dead. Most, but
not all, of the embryos died between E14.5 and E16.5and displayed several gross phenotypes with incom-
plete penetrance: small size (80% for E14.5 and E15.5
embryos), pale color (26%), asymmetric ocular lesions
(11%), and hemorrhagic edema (14%) (Figure 2A and
Figure S1 in the Supplemental Data available with this ar-
ticle online). Histopathology analysis of serial sections
revealed cardiovascular defects in all living E14.5–
E16.5 embryos analyzed (Figure 2B, [c] and [d]), whereas
no major abnormality was observed in other organs, in-
cluding the placenta (data not shown). Cardiac morpho-
genesis appeared normal at E12.5 (data not shown), but
Figure 1. Targeted Inactivation of Cdk2 and Cdk4 Genes
(A) Organization of the inactivated Cdk2 and Cdk4 loci after meiotic
recombination and a table of the screening of Cdk2+/2Cdk4+/2trans
(K2+/2K4+/2) backcrossed to wild-type mice.
(B) Analysis ofCdk2 andCdk4 loci. PCR analysis of genomic tail DNA
from pups generated by backcrossing Cdk2+/2Cdk4+/2trans mice.
These pups were mostly single heterozygous for Cdk2 (lane 1) or
Cdk4 (lane 3), and a few were double heterozygous Cdk2+/2
Cdk4+/2cis (lane 2). Southern blot analysis of tail genomic DNA
from wild-type (lane 1), Cdk4+/2 (lane 2), Cdk2+/2Cdk4+/2trans (lane
3), and Cdk2+/2Cdk4+/2cis (lane 4) mice. Cdk2 30 probe and Cdk4
50 probe were used as described in Experimental Procedures.
(C) Protein expression analysis by Western blots of Cdk2, Cdk4, and
b-actin by using extracts of wild-type,Cdk2+/2Cdk4+/2 (K2+/2K4+/2),
and DKO E13.5 embryos.
(D) Table for viability of Cdk22/2Cdk42/2 embryos at various stages
of development. *Observed ratios correspond to the number of
Cdk22/2Cdk42/2 embryos, alive (heart beating) and dead (in paren-
theses), compared to the total number of embryos harvested. Cdk2
and Cdk4 loci are linked; therefore, the expected percentage of
Cdk22/2Cdk42/2 embryos is 25%. At E17.5 and later, most of the
Cdk22/2Cdk42/2 embryos were dead and degraded, which pre-
cluded genotyping.
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Mice
(A) Appearance of wild-type and Cdk22/2
Cdk42/2 embryos at the indicated stages of
development. Wild-type littermates are
shown for comparison. Eye defects (arrow)
and edemas (*) occur with partial penetrance.
(B) Cardiovascular abnormalities in Cdk22/2
Cdk42/2 embryos. Appearance of isolated
heart from (a) wild-type and (b) Cdk22/2
Cdk42/2 embryos at E14.5 (the scale bar is 1
mm). Histological transversal sections
through the (c) wild-type and (d) Cdk22/2
Cdk42/2 heart in the plane of mitral valve
(mv) and papillary muscle (pm). Cdk22/2
Cdk42/2 hearts display atrium enlargement,
reduced thickness of the ventricle walls (com-
pact zone), and an interventricular septum
(ivs) with a ventricular septal defect (VSD)
(the scale bar is 1 mm). Compact zone of (e)
wild-type and (f) Cdk22/2Cdk42/2 ventricle
walls from the boxed area in (c) or (d). Cardio-
myocytes appear disorganized and hypertro-
phic in Cdk22/2Cdk42/2 embryos (the scale
bar is 20 mm). Immunodetection of BrdU on
transversal sections through hearts ([g] and
[h]; the scale bar is 100 mm). The right atrium
(ra), the left atrium (la), the right ventricle (rv),
the left ventricle (lv), and the triscuspid valve
(tv) are indicated.
(C) Organ size and BrdU incorporation in vivo
(S phase marker). Whole mounts of (a) lungs,
(b) liver, and (d) brain from E14.5 embryos
are shown (the scale bar is 1 mm). Analysis
by flow cytometry of BrdU-positive cells in
(c) liver and (e) brain are depicted. The bar
graph represents the absolute cell number
per total fetal liver/brain and total BrdU-posi-
tive cells (percentage of BrdU-positive cells3
total cells per fetal liver) for three wild-type or
Cdk22/2Cdk42/2 embryos at E14.5.it was severely affected at E14.5 (Figure 2B). Abnormali-
ties included reduced global size (Figure 2B, [a] and [b]),
enlargement of atria, thin ventricular walls, and hypertro-
phy of the valves. At the microscopic level, cardiomyo-
cytes seem to be differentiated, but hypertrophic and
disorganized (Figure 2B, [e] and [f]). Proliferation in cer-
tain areas of the heart was decreased in DKOs compared
to wild-type (Figure 2B, [g] and [h]). These defects were
most likely the origin of a cardiac output failure, some-
times triggering hemorrhages and, for most but not all
of the Cdk22/2Cdk42/2 embryos, lethality before E16.5.
Among other observations, the small size of the
Cdk22/2Cdk42/2 mutants was the most prevalent. Spe-
cific tissues, like lung, liver, or brain, indicated a size re-
duction as well (Figure 2C, [a], [b], and [d]). In order to
characterize this phenotype, embryos isolated at differ-
ent stages of development were examined for bromo-
deoxyuridine (BrdU) incorporation as a measure for
DNA replication/S phase. We first pulse-labeled E14.5
embryos with BrdU and then prepared a cell suspension
from liver or brain. The relative ratio of BrdU-positive
cells was determined by flow cytometry, and the total
number of BrdU-positive cells was calculated. We ob-served a 3-fold decrease of total BrdU-positive cells in
liver (Figure 2C, [c]) and a 2.6-fold decrease of total
BrdU-positive cells in brain (Figure 2C, [e]). This could
be one reason for the low cellularity in the liver or brain
and, most likely, for the similar defects existing in other
tissues, which could result in global size reduction ob-
served at E14.5 or at later stages. We also performed
TUNEL staining on sections of limbs or heart/lung and
detected comparable levels of apoptosis (see Fig-
ure S2), suggesting that the small size of Cdk22/2
Cdk42/2 embryos is probably linked to lower cell prolif-
eration rather than to apoptosis.
Hematopoiesis in Cdk22/2Cdk42/2 Embryos
Knockouts of G1 phase regulators, likeCdk42/2Cdk62/2
DKOs and cyclin D12/2D22/2D32/2 TKOs, display se-
vere hematopoietic defects (Kozar et al., 2004; Malum-
bres et al., 2004). A common feature of Cdk22/2Cdk42/2
embryos was their pale appearance, suggesting the
possibility of hematopoietic abnormalities. To investi-
gate the hematopoietic development in Cdk22/2Cdk42/2
embryos, we first examined fetal livers from wild-type
and DKO embryos at E14.5, since this is the major
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Cdk22/2Cdk42/2 Embryos
(A) Flow cytometry analysis of hematopoietic
stem cells (HSC), common myeloid progeni-
tors (CMP), granulocyte-macrophage pro-
genitors (GMP), and megakaryocyte-ery-
throid progenitors (MEP) isolated from E14.5
fetal livers. Relative percentages of selected
populations are shown. FSC, forward scatter.
(B) Bar graphs represent absolute cell num-
bers per fetal liver or indicated subpopula-
tions. Red cells were double positive for
CD71 and TER119 staining. Error bars repre-
sent the standard deviation of 14 analyzed
livers for the total cellularity and 3 different
DKO data for the progenitors and red blood
cells.
(C) 3H-thymidine proliferation assay gener-
ated with cells isolated from total fetal liver
and cultured in the presence of cytokines, en-
hancing multipotential progenitor growth. A
total of 5 3 103 cells were plated in triplicate
in a 96-well plate and were pulsed with 3H-thy-
midine after 2 and 5 days. Data are represen-
tative of three independent experiments ana-
lyzing seven fetal livers per genotype. Error
bars represent the standard deviation of three
different sets of data.
(D) Umbilical cord blood cells are shown. A to-
tal of 105 cells were cytocentrifuged on slides
and stained with Eosin/Azure A. The inset rep-
resents 2.3-fold magnification; the scale bar is
100 mm.hematopoietic organ at this stage of development. We
noticed that the cellularity was reduced 2.4-fold in
DKOs compared to wild-type fetal livers (Figure 3B). To
determine if low cellularity was associated with abnor-
mal hematopoiesis, we used flow cytometry to distin-
guish various hematopoietic cell types, including ery-
throid cells, macrophages, granulocytes, and B cells
(Figure 3B and data not shown). Similar percentages
were observed for all of these mature hematopoietic
cell types in wild-type and DKO fetal liver (data not
shown). Thus, the reduction in liver cellularity reflects
a loss in the total number of cells, which especially af-
fects red blood cells (CD71+/TER119+) (Figure 3B), given
that these cells represent 75% of the total cell population
of fetal liver. This fact on its own likely accounts for the
pale appearance of the DKO embryos. To investigate
the reasons for the reduced number of Cdk22/2Cdk42/2
fetal liver cells, we analyzed cells in the following hema-
topoietic compartments: hematopoietic stem cells
(HSC), which give rise to common myeloid progenitors
(CMP) that, in turn, produce granulocyte-macrophage
progenitors (GMP), and megakaryocyte-erythroid pro-
genitors (MEP) (Akashi et al., 2000). We found that
although the absolute number of hematopoietic progen-
itors was lower in DKO fetal livers, the relative percent-
ages of all of these progenitors were not significantlydifferent in DKOs compared to wild-type (Figures 3A
and 3B). We next characterized the proliferation of the
fetal liver cells by using a cytokine cocktail (mSCF, hFlt-
3L, mIL-3, mIL-6) to enhance multipotential progenitor
growth. Aslightproliferationdefect for DKO multipotential
progenitors was detected by thymidine incorporation
(Figure 3C). Nevertheless, the decreased growth rate did
not affect the potential of progenitors to form colonies in
soft agarose (WT, 16.2 6 3; DKO, 14.8 6 0.7; data not
shown). We concluded thatCdk22/2Cdk42/2 hematopoi-
etic cells are able to generate all progenitors and mature
cells from HSC, but do so to a lesser extent than wild-
type due to reduced proliferation of the multipotential
progenitors, which, consequently, affects the amount
of all other subpopulations.
To further characterize hematopoiesis in DKOs, we
examined blood cells isolated from the umbilical cord
of E14.5 embryos. As expected, fewer blood cells were
harvested from the umbilical cord of Cdk22/2Cdk42/2
embryos (data not shown), although normal ratios of dif-
ferent subpopulations of blood cells were detected, in
agreement with the flow cytometry analysis of fetal liver.
We noticed that most nucleated erythroid cells from
Cdk22/2Cdk42/2 mutants were larger than those iso-
lated from wild-type (Figure 3D). These enlarged cells
might represent primitive erythroblasts generated in
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erythroblasts have been generated (Kingsley et al.,
2004).
Molecular Analysis of Cdk22/2Cdk42/2 Embryos
In order to investigate the basis of lethality in Cdk22/2
Cdk42/2 embryos on a molecular level, we analyzed
protein extracts from living (heart beating) embryos at
E13.5, E14.5, or E16.5. We confirmed that Cdk2 and
Cdk4 proteins are expressed during embryogenesis in
wild-type embryos, but not inCdk22/2Cdk42/2 embryos
(Figure 4, first and second panels from top). The expres-
sion levels of p27 and Cdk6 were similar in wild-type and
DKOs, with a slight decrease at E16.5 in DKOs (Figure 4,
third and fourth panels from top). Cyclin D1 expression
displayed the same pattern with a more pronounced de-
crease in DKOs at E16.5 (Figure 4, fifth panel from top).
Interestingly, Cdc2 was expressed at a similar level at
E13.5, but the expression of Cdc2 decreased progres-
sively at E14.5 and E16.5 in Cdk22/2Cdk42/2 compared
to wild-type embryos (Figure 4, sixth panel from top). The
decreased Cdc2 expression is associated with a pro-
gressive reduction of Cdc2 activity (see Figure S3). We
observed a similar expression pattern for cyclin A2 (Fig-
ure 4, sixth panel from bottom). Since Cdc2 and cyclin A2
are targets of E2F-mediated transcription, we next
checked the status of Rb and E2F. Expression of E2F
and Rb was comparable in all embryo extracts (Figure 4,
fifth and third panels from bottom). In contrast, phos-
phorylation of Rb at serine 780, a Cdk4-specific site,
was decreased at E14.5 and was undetectable at E16.5
in Cdk22/2Cdk42/2 compared to wild-type embryos
(Figure 4, fourth panel from bottom). This result indicates
that the phosphorylation of Rb requires Cdk2 or Cdk4;
however, it also pointed out that, in early embryogenesis
(before E14), other kinases can phosphorylate Rb (see
Discussion). We immunoprecipitated cyclin D1 com-
plexes from embryo extracts and observed more Cdk6
bound in DKOs compared to wild-type extracts at E13.5
and E14.5 (Figure 4, bottom panel). This result suggests
that the absence of Cdk4 (and Cdk2) leaves cyclin D1
available for binding to Cdk6, which might compensate
for, to a certain extent, the lack of Cdk4. At E16.5, this
compensation was no longer observed due to the de-
creased expression of cyclin D1 (see fifth panel from top).
Proliferation of Cdk22/2Cdk42/2 Embryonic
Fibroblasts
To evaluate the loss of Cdk2 and Cdk4 on a cellular level,
we generated mouse embryonic fibroblasts (MEFs) to
analyze cell proliferation and cell cycle regulation. At
passage 2 (P2), Cdk22/2Cdk42/2 MEFs proliferated at
a lower rate than did Cdk2+/2Cdk4+/2 (data not shown)
or wild-type MEFs (Figure 5A, upper panel). At P4, prolif-
eration of Cdk22/2Cdk42/2 MEFs was very low (Fig-
ure 5A, lower panel). To determine the percentage of
cells in the different phases of the cell cycle, unsynchro-
nized P2 MEFs were pulse labeled with BrdU and ana-
lyzed by flow cytometry. We found that 7% of the
Cdk22/2Cdk42/2 cells were in S phase compared to
22% of the wild-type MEFs (see Figure S4), indicating
a G1/S transition defect. To investigate the S phase entry
defect further, MEFs were synchronized by contact inhi-
bition/serum starvation, released into fresh medium,labeled with BrdU, and analyzed by flow cytometry
(Figure 5B). We found that wild-type cells began entering
S phase at 15 hr after release (8.4%6 0.3%) and reached
a maximum after 24 hr (34.3%6 2.3%). In contrast, only
2.7% 6 1.2% of the Cdk22/2Cdk42/2 MEFs were BrdU
positive at 15 hr, and no more than 8.2%6 1.1% positive
cells were observed after 24 hr. This result indicates that
the low proliferation rate of Cdk22/2Cdk42/2 MEFs, ob-
served as early as P2, correlates with a reduced percent-
age of cells entering S phase. In parallel, we investigated
whether DKO cells displayed senescent features (flat
and enlarged morphology or senescent-associated
[SA]-b-galactosidase staining; Dimri et al., 1995). A
2-fold increase of b-galactosidase-positive (blue) cells
was observed in DKOs compared to wild-type MEFs at
P2 and P4 (Figure 5C). Overall, these results suggest
that loss of Cdk2 and Cdk4 affects cellular proliferation.
Indeed, the lack of Cdk2 and Cdk4 influences S phase
entry of MEFs at early passages and triggers premature
senescence at late passages. Both defects result in a low
proliferation rate, which decreases progressively with
each passage in culture.
Figure 4. Molecular Analysis of Cdk22/2Cdk42/2 Embryos
Western blot analysis of extracts prepared from wild-type or living
Cdk22/2Cdk42/2 embryos at E13.5, E14.5, and E16.5 with indicated
antibodies. Immunoprecipitation of cyclin D1 followed by a Cdk6
Western blot is shown in the bottom panel.
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(A) Proliferation of MEFs was analyzed for 8 days with AlamarBlue
assays at passages 2 (upper panel) and 4 (lower panel). Error bars
represent the standard deviation of the data from the clone number
indicated in the figure: P2 WT (six clones), P2 DKO (seven clones), P4
WT (8 clones), P4 DKO (8 clones). Data represent the average of
three clones (WT and Cdk2+/2Cdk4+/2) and six clones (DKO),
respectively.
(B) S phase entry analysis of synchronized MEFs. After serum star-
vation, cells were released at time 0 hr and labeled with BrdU at
the indicated time; the percentage of cells in S phase was deter-
mined by flow cytometry analysis.
(C) Senescent-associated (SA)-b-galactosidase staining of MEFs at
passages 2 and 4. Cells were stained for SA-b-galactosidase after
incubation for 24 hr. Data were the average compiled from three
wild-type and five DKO clones; at least 200 cells were counted
from each clone.Rb/E2F Repression Contributes to Lack
of Proliferation
Entry into S phase requires phosphorylation of Rb by cy-
clin/Cdk complexes whereupon phospho-Rb is released
and E2F is activated (Trimarchi and Lees, 2002). Cdk2
and Cdk4 are among the kinases best characterized to
phosphorylate Rb; however, recent in vivo studies have
demonstrated the plasticity of Cdk redundancy, indicat-
ing that Cdc2 might compensate for Cdk2 (Aleem et al.,
2005). In order to determine the molecular mechanism
responsible for the Cdk22/2Cdk42/2 proliferation de-
fects, we examined MEFs at P2 and P4 for the expression
of Cdc2 complexes and E2F-target genes as we had
done in embryo extracts (see Figure 4). We immunopre-
cipitated Cdc2 complexes and observed a decrease of
Cdc2 protein expression level in DKO MEFs at P2; and
this expression level was more pronounced at P4 (Fig-
ure 6A, top panel). Similarly, lower amounts of Cdc2
were detected in DKOs compared to wild-type MEFs af-
ter immunoprecipitation with Suc1, cyclin A2, or cyclin
B1 antibodies (Figure 6A, second, third, and fourth panels
from top). We also verified the expression levels of Rb,
which was unchanged (Figure 6A, fourth panel from bot-
tom), but phosphorylation of Rb at serine 780, serine
807/811, and threonine 821 was decreased in DKOs com-
pared to wild-type MEFs (Figure 6A, bottom three panels).
If E2Fs are not released from Rb, we should be able to
observe inhibition of Cdc2 and expression of other E2F-
target genes at the transcriptional level. Indeed, RT-PCR
analysis indicated a decreased expressionofCdc2,cyclin
E2, cyclin A2, cyclin B1, and Cdc25A mRNA in Cdk22/2
Cdk42/2 MEFs compared to wild-type (Figure 6B, first,
third, fourth, fifth, and sixth panels from top). This de-
crease was more accentuated at P4 than at P2. In con-
trast, cyclin E1 expression was not affected (Figure 6B,
second panel from top). Among the pocket proteins, Rb
and p130 were slightly downregulated, and p107 expres-
sion was reduced in DKO MEFs (Figure 6B, seventh,
eighth, and ninth panels from top). However, expression
of Rb protein was comparable in wild-type and DKO
MEFs, suggesting thatmolecular regulationofRb isdiffer-
ent than for other E2F-target genes. We have also exam-
ined the RNA expression of Cdk inhibitors and observed
a similar increase of p16INK4a at P4 in wild-type and DKO
MEFs, which probably reflects the senescence pheno-
type (Figure 6B, fifth panel from bottom). The levels of
others Cdk inhibitors, p19INK4d, p21CIP1, and p27KIP1,
were decreased in DKOs compared to wild-type MEFs
(Figure 6B, second, third, and fourth panels from bottom).
A similar reduction of Cdk inhibitors has been observed in
Cdk42/2Cdk62/2MEFs (Malumbres etal., 2004), suggest-
ing a feedback mechanism that reduces the overall levels
of cell cycle inhibitors in the absence of normal levels of
Cdks. Since E2F-target genes are responsible for entry
intoS phase and for cell cycle progression, the downregu-
lation of Cdc2 and other E2F-target genes in Cdk22/2
Cdk42/2MEFs likely accounts for the observed prolifera-
tion defects.
Rescue of Proliferation Defects in Cdk22/2Cdk42/2
MEFs
Our results so far indicate that there is a defect in the Rb/
E2F pathway in DKO MEFs. To analyze this further, we
wondered whether inactivation of Rb by expressing
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fect (Figure 7A, left panel). Expression of HPV-E7 not only
rescued the proliferation defect, but it also restored the
protein levels of Cdc2 and cyclin A2 in DKOs to levels
comparable to those of wild-type MEFs (Figure 7A, right
panel). Although p27 RNA and Cdc2 protein expression
is reduced in DKOs, we wanted to investigate if the
loss of p27 would rescue proliferation since we have
shown that Cdc2 activity is controlled by p27 and can
regulate the G1/S transition in the absence of Cdk2
(Aleem et al., 2005). We generated TKOs, and, similar
to what is seen with DKOs, Cdk22/2Cdk42/2p272/2 em-
bryos were normal at E13.5 and died around E15.5 (data
not shown). TKO Cdk22/2Cdk42/2p272/2 MEFs were
analyzed, and we found that the loss of p27 did not res-
cue the proliferation defects of the DKO MEFs
(Figure 7B). To verify that the proliferation defect in the
DKOs is directly related to the loss of Cdk2, we ex-
pressed Cdk2-HA in DKO MEFs, thereby generating
‘‘Cdk42/2’’ MEFs. As expected, expression of Cdk2 in
DKO MEFs restored proliferation in DKO MEFs to levels
comparable to wild-type MEFs (Figure 7B). We also in-
vestigated if the premature senescence phenotype was
correlated to Rb functions. Expression of HPV-E7 or
Cdk2 restored the levels of senescence in DKO MEFs
to wild-type levels (Figure 7C). In addition, spontaneous
immortalization by passaging MEFs according to the 3T3
Figure 6. Expression of E2F-Target Genes in Cdk22/2Cdk42/2
MEFs
(A) Immunoprecipitations (IP) and Western blotting analysis of MEF
extracts at passages 2 (lanes 1 and 2) and 4 (lanes 3 and 4) with in-
dicated antibodies. Western blots of Rb phosphorylation sites
(Ser780, Ser807/811, and Thr821) are shown in the bottom three
panels.
(B) Expression analysis of indicated genes by RT-PCR from total
MEF RNA at passages 2 (lanes 2 and 3) and 4 (lanes 4 and 5). Lane
1: 1 kb ladder II (Gene Choice, #62-6108-28). Lane 6: water control
(ct-). All oligonucleotides used are listed in Table S1.protocol (Todaro and Green, 1963) was analyzed. DKO
and TKO MEFs were unable to become immortalized
and stopped growing after w10 passages (Figure 7D).
Expression of HPV-E7 restored the immortalization of
DKOs to wild-type levels.
These experiments are based on the fact that HPV-E7
inactivates Rb, but there have been indications that
HPV-E7 might have also other functions that could influ-
ence the outcome of our experiments (for a review, see
Mu¨nger and Howley, 2002). Therefore, we made use of
a number of HPV-E7 mutants, some of which are unable
to bind Rb (residues 22–26 of HPV-E7 include the core Rb
binding site [LXCXE]). None of the HPV-E7 mutants de-
fective in Rb binding (D21–24, C24G, E26G) rescued
the proliferation (Figure 7E) or immortalization (data not
shown) of DKO MEFs; however, other HPV-E7 mutants
(D1–6 [amino-terminal CR1 homology domain necessary
for cellular transformation], C91S [carboxyl-terminal zinc
binding domain of E7 implicated in protein dimerization
and stability]) partially rescued the proliferation of DKO
MEFs (Figure 7E) but did not rescue immortalization
(data not shown). These HPV-E7 mutants confirm that,
most likely, the loss of Rb phosphorylation by Cdk2
and Cdk4 and the resulting repression of E2F transcrip-
tion are the primary causes of the observed cell cycle de-
fect in DKO MEFs. Nevertheless, we cannot exclude that
other functions of HPV-E7 contribute to the rescue too.
Discussion
In this study, we have investigated the genetic interac-
tions and functional overlap of Cdk2 and Cdk4 in vivo.
We have generated Cdk22/2Cdk42/2 DKOs and ob-
served that they die in utero around E15, most likely as
a result of heart defects. The loss of Cdk2 and Cdk4
causes hypophosphorylation of Rb, which leads to re-
pression of E2F-target gene expression. For example,
Cdc2 and cyclin A2 cease to be expressed, resulting in
a cell cycle defect. This most likely caused reduced pro-
liferation, a premature senescent phenotype, and resis-
tance to immortalization in Cdk22/2Cdk42/2 cells. To
our knowledge, this is the first time that Cdk2 and Cdk4
are shown to be important for the regulation of Rb in
vivo by using genetics, and that, indirectly, they are es-
sential for Cdc2 expression.
Recently, using Cdk22/2p272/2 mice, we have shown
that Cdc2 can compensate for the loss of Cdk2 (Aleem
et al., 2005). Cdc2 interacts with cyclin E (Aleem et al.,
2005; Koff et al., 1991) and is able to promote S phase en-
try. If Cdc2 is able to compensate for Cdk2, why is Cdc2
unable to rescue Cdk22/2Cdk42/2 mutants? Our results
suggest that Cdc2 expression is turned off in DKOs be-
cause Cdc2 transcription is regulated by E2Fs (Dalton,
1992). E2F regulation of Cdc2 was previously known,
but given the fact that Cdc2 protein levels are constant
and high, the importance of this kind of Cdc2 regulation
was overlooked. Our results indicate that there is cou-
pling of the G1 phase with mitosis through the transcrip-
tional regulation of Cdc2: Cdk2 and Cdk4 control the ex-
pression of Cdc2 (through Rb/E2F). Our experiments
with Cdk22/2Cdk42/2 DKOs suggest that Rb/E2F con-
trol of Cdc2 expression is essential in vivo. Most likely,
Cdk22/2Cdk42/2mutants die because Cdc2 expression
is lost at the same time. Therefore, the transcriptional
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cued by HPV16-E7
(A) Proliferation analysis of MEFs infected
with HPV16-E7 at passage 4. Proliferation
was analyzed for 7 days with AlamarBlue as-
says (left panel). Noninfected MEFs or MEFs
infected with control vector (data not shown)
behave similarly. Cells were harvested after
selection, extracts were prepared, and West-
ern blots were performed with indicated anti-
bodies (right panel). Error bars represent the
standard deviation of the data from the clone
number indicated in the figure: WT, DKO,
WT + E7, DKO + E7 (two clones each).
(B) Proliferation analysis at passage 2 of TKO
Cdk22/2Cdk42/2p272/2 MEFs (TKO) and
MEFs infected with Cdk2-HA. MEFs infected
with control vector (data not shown) behave
similarly to wild-type or p272/2 MEFs. Error
bars represent the standard deviation of the
data from the clone number indicated in the
figure: WT (four clones), DKO (2 clones),
p272/2 (five clones), TKO (two clones), DKO +
Cdk2 (two clones).
(C) SA-b-galactosidase staining of wild-type
MEFs (left column) and DKO MEFs (right col-
umn) infected with control vector, HPV16-E7,
or Cdk2-HA at passage 4 as described in Fig-
ure 5 (the scale bar is 200 mm). Error bars rep-
resent the standard deviation of the data
from the clone number indicated in the figure:
WT (four clones), DKO (five clones), DKO + E7
(two clones), TKO (two clones).
(D) Immortalization of wild-type, DKO, TKO, and
HPV16-E7-infectedDKO MEFsbyusing the3T3
protocol. Cumulative cell numbers over 10–13
passages were plotted; therefore, crisis, which
occurred around passages 6–10 is not easily
apparent. DKOs infected with control vector
behave similarly to DKO MEFs, and wild-type
MEFs infected with HPV16-E7 behave similarly
to wild-type MEFs (data not shown).
(E) Proliferation analysis of wild-type and DKO
MEFs infectedwithHPV16-E7orHPV16-E7mu-
tants (M1, D1–4; M2, D21–24; M3, C24G; M4,
E26G; M5, C91S) at passage 4. Mutants M2–
M4 affect HPV16-E7 Rb binding. Wild-type
MEFs infected with HPV16-E7 mutants (data
not shown) behave similarly to wild-type MEFs.control of Cdc2 is important for its protein expression
levels in vivo. It remains to be seen whether expression
of Cdc2 from a heterologous promoter would rescue
some of the Cdk22/2Cdk42/2 phenotypes.
Cdk22/2Cdk42/2 cells display proliferation defects,
but why can they proliferate at all? In early embryogene-
sis, proliferation seems close to normal, and Rb is phos-
phorylated on serine 780 (see Figure 4, lane 2) inCdk22/2
Cdk42/2 mutants. We can envision two possibilities for
the phosphorylation of Rb in the absence of Cdk2 and
Cdk4, which would involve Cdk6 and/or Cdc2. In the ab-
sence of Cdk4, we have detected more cyclin D1/Cdk6
complexes in comparison to wild-type (see Figure 4, bot-
tom panel). These cyclin D1/Cdk6 complexes most likely
contribute to the phosphorylation of Rb. Nevertheless, in
E16.5 embryos, we did not detect cyclin D1 complexes
anymore because cyclin D1 protein expression is de-
creased (Figure 4, lane 6). Similarly, it is possible that
Cdc2 complexes contribute to the phosphorylation of
Rb since Cdc2 displays a substrate specificity compara-ble to that of Cdk2. Cdc2 protein (see Figure 4, lane 2),
complexes, and activity were detectable in early DKO
and wild-type embryos. At a time when phosphorylation
of Rb starts to decline, the E2F-target gene transcription
decreases, and, as a consequence, Cdc2 might not be
able to phosphorylate Rb as efficiently, enhancing the
negative feedback loop to arrest the cell cycle.We cannot
exclude that another (unknown) kinase contributes to Rb
phosphorylation in early embryogenesis, but we believe
that Cdk6 and/or Cdc2 are the most likely candidates.
Cdk22/2Cdk62/2 DKO mice are viable (Malumbres
et al., 2004), and, in contrast, we have shown here that
Cdk22/2Cdk42/2 mutants are embryonic lethal. This in-
dicates intrinsic differences between Cdk4 (in the case
of Cdk22/2Cdk62/2) and Cdk6 (in the case of Cdk22/2
Cdk42/2). Cdk4 or Cdk6 are required for viability since
Cdk42/2Cdk62/2 mutants are lethal (Malumbres et al.,
2004). One could envision that this is because the
expression of Cdk6 is much more restricted compared
to Cdk4, giving a potential explanation for the heart
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571defect; however, in MEFs, that is actually not the case.
Therefore, it is likely that Cdk4 can phosphorylate Rb
more efficiently than Cdk6, or that Cdk4 has other sub-
strates compared to Cdk6. It will be interesting to identify
these molecular differences between Cdk4 and Cdk6 in
the future.
Our results indicate the importance of an in vivo func-
tional overlap between Cdk2 and Cdk4 in the regulation
of the Rb/E2F pathway during normal development. It
will be interesting to investigate whether the Cdk2/
Cdk4 redundancy is also essential during tumorigenesis
since silencing of Cdk2 in certain tumor cell lines had no
effect on the proliferation of these cells (Tetsu and Mc-
Cormick, 2003).
Experimental Procedures
Generation of Cdk22/2Cdk42/2 Mice
Cdk2+/2 mice were crossed with Cdk4+/2 mice (Berthet et al., 2003;
Tsutsui et al., 1999). Heterozygous offspring Cdk2+/2Cdk4+/2trans
mice were backcrossed with C57BL/6 mice to produce Cdk2+/2
Cdk4+/2cis mice, which were, in turn, intercrossed to generate homo-
zygous mutantCdk22/2Cdk42/2animals. The mice used in this study
were of mixed C57BL/63 129S1/SvlmJ background. Mice were rou-
tinely genotyped by isolating tail DNA with HOTshot lysis (Truett
et al., 2000) and PCR with Cdk2 oligonucleotides (F: 50-GTGA
CCCTGTGGTACCGAGCACCTG-30 [PKO0292]; R: 50-GGTTTTGCTC
TTGGATGTGGGCATGG-30 [PKO0344]; Neo: 50-CCCGTGATATTGC
TGAAGAGCTTGGCGG-30 [PKO0294]) and Cdk4 oligonucleotides
(F: 50-CGGAAGGCAGAGATTCGCTTAT-30 [PKO0104]; R: 50-CCAGC
CTGAAGCTAAGAGTAGCTGT-30 [PKO0105]; Neo [PKO0294]) for 30
cycles at 94ºC for 30 s and 62ºC for 60 s. Southern blots were per-
formed occasionally to confirm genotyping, by using Cdk2 50 or 30
probes and the Cdk4 50 probe previously described (Berthet et al.,
2003; Tsutsui et al., 1999). Cdk2+/2Cdk4+/2cis mice were crossed to
p27+/2 (Kiyokawa et al., 1996) to generate TKOs. Genotyping of
p27 was performed as described (Aleem et al., 2005). Mice were
group-housed under standard conditions with food and water avail-
able ad libitum and were maintained on a 12 hr light/dark cycle. Mice
were fed a standard chow diet containing 6% crude fat and were
treated in compliance with the National Institutes of Health guide-
lines for animal care and use.
Histopathology and Immunohistochemistry
Organs were dissected, fixed in 10% neutral buffered formalin (Ac-
custain from Sigma-Aldrich, USA), and embedded in paraffin. Sec-
tions were stained with hematoxylin and eosin (H&E). For analysis
of proliferation, mice were injected intraperitoneally with BrdU (100
mg bromodeoxyuridine per kilogram body weight), and tissues
were collected after 1 hr, fixed in 70% ethanol, and embedded in par-
affin. Paraffin sections were stained with antibodies against BrdU
(DAKO, Cat# M0744) at a concentration of 27 mg/ml, followed by de-
tection with the Vectastain ABC kit (Vector Laboratories, CA, USA).
For flow cytometry analysis, BrdU-injected embryos were harvested
as described above, and liver and brain were isolated. Cell suspen-
sions were prepared as described below. Cells were counted and
fixed in 70% ethanol. BrdU and propidium iodide staining were per-
formed as described (Berthet et al., 2003).
Analysis of Hematopoietic Progenitors in Fetal Liver
Fetal livers were dissected from E14.5 embryos, dissociated, and
passed through fine mesh (BD Falcon, #352340) to generate a single
cell suspension. The cells were resuspended at a density of 1 3 106
cells/100 ml in PBS with 0.1% BSA (Sigma-Aldrich, St. Louis, MO),
and they were stained with fluorescein isothiocyanate-conjugated
CD34 (RAM34), phycoerythrin-conjugated anti-c-Kit (2B8), phycoery-
thrin-Cy5-conjugated FcgRII/III (2.4G2; Pharmingen, San Diego, CA),
and allophycocyanin-conjugated anti-Sca-1 (Ly-6A/E) monoclonal
antibodies (eBioscience, San Diego, CA) to distinguish HSC, CMP,
GMP, and MEPpopulations, respectively.Toexclude terminallydiffer-
entiated hematopoietic cells, cells were stained with biotinylated anti-
bodies specific for the following lineage markers: CD33, CD4, CD8,B220, and TER119 (Pharmingen, San Diego, CA). Biotinylated
IL-7Ra (A7R34) antibody was added to this cocktail to exclude fetal
liver common lymphoid progenitors (CLP), and the cells were then
stained with avidin-PerCP-Cy5.5. Throughout staining, the cells were
kept at 4ºC, and the antibodies were used at a concentration of 0.5mg/
13 106 cells. All cell populations were analyzed by using a FACS LSRII
(Becton Dickinson Immunocytometry, Mountain View, CA).
The proliferative response of fetal liver cells to hematopoietic
growth factors was measured with a 3H-thymidine proliferation as-
say. Cells were washed three times in complete medium and plated
at 53 103 cells per well per 100 ml in triplicate in either complete me-
dium with no growth factors or complete medium with 100 ng/ml
mSCF, 30 ng/ml mIL-3, 100 ng/ml hFlt-3 ligand, and 50 ng/ml mIL-6
(all growth factors from Peprotech, Rocky Hill, NJ, USA). After 2
and 5 days in culture, cells were pulsed with 1 mCi 3H-thymidine per
well (6.7 Ci/mmol, Perkin Elmer Life Sciences, Inc., Boston, MA)
and incubated for an additional 16 hr. To measure 3H-thymidine in-
corporation, the cells were harvested onto glass-fiber filtermats (Fil-
termat A; Wallac Oy, Turku, Finland) by using a Tomtech Harvester 96
(Tomtech, Inc., Orange, CT), and the filters were allowed to dry over-
night. Radioactivity was counted by using BetaPlate Scint liquid
scintillation fluid (Perkin Elmer) and a 1205 Betaplate liquid scintilla-
tion counter (LKB Wallac, Perkin Elmer).
Isolation and Culture of Embryonic Fibroblasts
Fibroblasts were prepared from embryos at 13.5 days postcoitum as
described previously (Berthet et al., 2003). The cell suspension from
each individual embryo was seeded in 100 mm culture dishes (pas-
sage 0). MEFs were routinely cultured in a humidified 5% CO2 atmo-
sphere at 37ºC in Dulbecco’s modified minimum essential medium
(DMEM, Invitrogen, #10569-010) supplemented with 10% (w/v) fetal
calf serum (FBS; Gemini Bio-Products, #100-106) and 1% penicil-
lin/streptomycin (Invitrogen, #15140-122). Proliferation of MEFs
was analyzed in 96-well plates with 1500 cells/well (triplicate for
each clone/day) and scored by using the AlamarBlue assay (Bio-
source, DAL1100) (Ahmed et al., 1994). Complete medium with
10% AlamarBlue was added to each well, and a fluorescent reading
was carried out 4 hr later. Cell cycle synchronization by serum star-
vation and BrdU incorporation were performed as described (Berthet
et al., 2003). Cells were harvested at the indicated time points after
serum addition, washed with cold PBS and frozen in nitrogen for pro-
tein or RNA analysis, or fixed in 70% ethanol for flow cytometry anal-
ysis. Cell cycle analysis after propidium iodide and BrdU staining was
performed as described (Berthet et al., 2003). Senescence analysis
has been performed according to the original protocol (Dimri et al.,
1995). A total of 104 cells were plated in a Lab-Tek II chamber slide
(Nalgen Nunc International, #154461) and 24 hr later were washed
with PBS, fixed in 2% formaldedyde/0.2% glutaraldehyde for 5 min
at room temperature, washed with PBS, and incubated overnight
at 37ºC with 0.2 mm filtered SA-b-galactosidase solution (PBS/citric
acid [pH 6], 5 mM potassium ferrocyanide, 5 mM potassium ferricy-
anide, 150 mM NaCl, 2 mM MgCl2, 1 mg/ml X-Gal [Promega,
#V3941]). Slides were counterstained with 0.1% Neutral Red (83%
Neutral Red dye; Matheson, Coleman and Bell, #B36-NX260) in
dH2O for 1 min, rinsed, and dehydrated in 100% ethanol (three
changes). Then slides were placed in Xylene (four changes), and cov-
erslips were mounted with Permount (Fisher).
Retroviral Infection of MEFs
The human Cdk2-HA ORF and viral HPV16-E7 were cloned into the
BamHI site of the retroviral vector pBabe (PKB722 and PKB841, re-
spectively). HPV16-E7 mutants (D1–4, D21–24, C24G, E26G, C91S)
are cloned into retroviral pBabe vector and were a kind gift of Karl
Mu¨nger. Plasmids were transfected into the packaging cell line Eco
Phoenix by using Lipofectamine 2000 (Invitrogen, #11668-019). After
48 and 72 hr, MEFs were infected with 3 ml of the supernatant of Eco
Phoenix cells containing viral particles in the presence of 8 mg/ml
polybrene (Sigma, # H-9268) and were allowed to grow for 2 more
days. The infected MEFs were selected for 4 days with 2.5 mg/ml pu-
romycin (Sigma, # 82595) and were plated for the experiments.
Protein Analysis
Proteins from embryos or MEFs were isolated at 4ºC by using a Teflon
potter homogenizer and the following lysis buffer: 50 mM HEPES
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phosphate, 0.1% Tween 20, 10% glycerol, 1 mM DTT, 2 mM NaF,
13 protease inhibitors (10 mg/ml each of leupeptin, chymostatin,
and pepstatin [Chemicon, Temecula, CA]). Lysates were centrifuged
for 45 min at 18,0003g at 4ºC, and supernatants were frozen in liquid
nitrogen. Protein concentrations were determined by using the Brad-
ford protein assay (Biorad, #500-0006). Lysates were analyzed by im-
munoblotting, immunoprecipitation, and kinase assays by using the
substrate histone H1 as previously described (Berthet et al., 2003).
Affinity-purified antibodies against Cdk2, Cdc2, Cdk4, Cdk6, and cy-
clin B1 have been described (Berthet et al., 2003). Other antibodies
are commercially available: rabbit anti-cyclin A (0.2 mg/ml, Santa
Cruz, H-432, #Sc-751), rabbit anti-cyclin D1 (2 mg/ml, NeoMarkers,
#RB-010-P), rabbit anti-Cdk4 (0.1 mg/ml, Clontech, #3517-1), rabbit
anti-E2F1 (0.4 mg/ml, Santa Cruz, C-20, #Sc-193), rabbit anti-p27
(0.5 mg/ml, Zymed, #71-9600), mouse anti-Rb (0.2 mg/ml, BD Phar-
Mingen, G3-245, #554136), rabbit anti-phospho-RbSer780, RbS807/811
(1:1000, Cell Signaling, #9307/8), rabbit anti-phospho-RbThr821
(1:1000, Biosource, #44-582G), goat anti-b-actin (0.4 mg/ml, Santa
Cruz, I-19, #Sc-1616). For immunoprecipitation, 10 ml antibodies
conjugated to agarose beads were used (available at Santa Cruz,
#Sc-xxx-AC) as well as anti-Rb-agarose beads (Santa Cruz, IF8,
#Sc-102) orp13Suc1-agarosebeads (UpstateBiotechnology, #14-132).
RNA Analysis
Total RNA was isolated from primary MEFs by using the Trizol reagent
(Life Technologies, #15596) according to the manufacturer’s instruc-
tions. cDNAs were generated with reverse transcriptase (SuperScript
II, Invitrogen, #18064014) by using 1 mg total RNA at 42ºC for 1 hr and
1.25 mM oligo-dT16 primers according to the manufacturer’s instruc-
tions. cDNAs were amplified by using specific primers (Table S1) for
25 cycles at 94ºC for 30 s, 55ºC for 30 s, and 72ºC for 60 s. PCR prod-
ucts were analyzed by electrophoresis on 3% agarose gels.
Supplemental Data
Supplemental Data including descriptions of ocular lesions, apopto-
sis, the activity of Cdk/cyclin complexes, and FACS analysis of MEFs
are available at http://www.developmentalcell.com/cgi/content/full/
10/5/563/DC1/.
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